Ondine Biomedical (LON:OBI) Trading Down 2.3% – Time to Sell?

Ondine Biomedical Inc. (LON:OBI)’s stock price was down 2.3% during mid-day trading on Thursday . The stock traded as low as C$10.10 and last traded at C$10.50. Approximately 1,064 shares were traded during trading, a decline of 100% from the average daily volume of 340,807 shares. The stock had previously closed at C$10.75.

Ondine Biomedical Trading Down 2.3%

The stock has a market cap of C$5.46 billion, a price-to-earnings ratio of -1.50 and a beta of 0.32. The company has a quick ratio of 8.26, a current ratio of 0.97 and a debt-to-equity ratio of 76.45. The business has a 50-day moving average of C$9.90 and a 200-day moving average of C$10.94.

Ondine Biomedical Company Profile

Ondine Biomedical is a life sciences company leading the charge in breakthrough photodisinfection-based therapies to prevent and treat serious infections, including those caused by existing, emerging, and antimicrobial-resistant pathogens.

Our vision is a world free from infections. We have created a patented, platform technology (photodisinfection) to provide simple solutions to complex infections across different therapeutic areas in healthcare and industry settings. We are focused on solutions that address significant needs, are easy to deploy, are environmentally safe, provide substantial public health benefits, and cost a fraction of the infections they target.

Our photodisinfection technology has been used successfully for many years in more than 100,000 patient treatments in hospitals, clinics, and industrial settings across Canada.